How Liraglutide and Semaglutide Protect the Heart: It Is Not Just About Blood Sugar
Causal mediation analysis of LEADER and SUSTAIN-6 reveals that GLP-1 drug cardiovascular benefits are only partly explained by HbA1c, blood pressure, and kidney markers, with effects varying over time.
Quick Facts
What This Study Found
HbA1c, UACR, and systolic blood pressure only partially mediate GLP-1 RA cardiovascular benefits, with time-varying effects that differ between liraglutide and semaglutide and across patient subgroups.
Key Numbers
LEADER: 9,340 subjects. SUSTAIN-6: 3,297 subjects. Ages ~64. Causal mediation analysis for HbA1c, UACR, and SBP effects on 3P-MACE over time.
How They Did This
Post hoc causal mediation analysis of the LEADER (liraglutide) and SUSTAIN-6 (semaglutide) randomized controlled trials, assessing time-varying mediation of 3P-MACE outcomes.
Why This Research Matters
Understanding why GLP-1 drugs protect the heart helps identify who benefits most and may reveal new cardiovascular protection mechanisms that could be targeted by future drugs.
The Bigger Picture
The cardiovascular benefits of GLP-1 drugs appear to go beyond just improving metabolic numbers. Identifying the additional mechanisms could lead to new cardiovascular therapies.
What This Study Doesn't Tell Us
Post hoc analysis — findings are hypothesis-generating. Mediation analysis has inherent assumptions about causal pathways that may not hold. Unmeasured confounders may exist.
Questions This Raises
- ?What unknown mechanisms explain the cardiovascular benefits not captured by HbA1c, UACR, and blood pressure?
- ?Do anti-inflammatory effects of GLP-1 drugs account for the unexplained cardiovascular protection?
Trust & Context
- Key Stat:
- Only partially mediated Traditional metabolic factors (HbA1c, blood pressure, kidney markers) explain only part of GLP-1 drug cardiovascular benefits
- Evidence Grade:
- Post hoc mediation analysis of two landmark RCTs — sophisticated statistical methodology applied to high-quality data, but inherently hypothesis-generating.
- Study Age:
- Published in 2025, applying modern causal inference methods to data from the foundational LEADER and SUSTAIN-6 trials.
- Original Title:
- Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.
- Published In:
- Cardiovascular diabetology, 24(1), 465 (2025)
- Authors:
- Peng, Zi-Yang, Lee, Yu-Hsuan, Ou, Huang-Tz, Kuo, Shihchen
- Database ID:
- RPEP-13014
Evidence Hierarchy
Frequently Asked Questions
How do GLP-1 drugs protect the heart?
This study shows that traditional explanations — lowering blood sugar, blood pressure, and kidney damage — only partly explain the cardiovascular benefits. Additional mechanisms, possibly including direct anti-inflammatory effects on blood vessels, likely contribute.
Do liraglutide and semaglutide protect the heart the same way?
Not exactly. The mediation effects differed between the two drugs and varied over time. This suggests that different GLP-1 RAs may have distinct cardiovascular protection profiles.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13014APA
Peng, Zi-Yang; Lee, Yu-Hsuan; Ou, Huang-Tz; Kuo, Shihchen. (2025). Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.. Cardiovascular diabetology, 24(1), 465. https://doi.org/10.1186/s12933-025-03007-w
MLA
Peng, Zi-Yang, et al. "Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.." Cardiovascular diabetology, 2025. https://doi.org/10.1186/s12933-025-03007-w
RethinkPeptides
RethinkPeptides Research Database. "Temporal and subgroup disparities in mediation effects on ca..." RPEP-13014. Retrieved from https://rethinkpeptides.com/research/peng-2025-temporal-and-subgroup-disparities
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.